On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 02/13/23
- ZIM Integrated falls -8.3%
- 11/16/22
- ZIM Integrated rises 10.7%
- 08/31/22
- ZIM Integrated to supply ten LNG-fueled vessels to Shell
- 08/17/22
- ZIM Integrated falls -8.5%
- 08/15/22
- Tiger Global buys Alphabet Class A, exits Zoom Video in Q2
- 01/24/23
- Zillow introduces feature enabling renters to schedule tours 'instantly, online'
- 01/19/23
- Redfin: Median U.S. home-sale price increased 0.9% for four weeks ending Jan. 15
- 01/05/23
- Redfin: Pending U.S. home sales dropped 32% y/y during four weeks ending Jan1
- 12/08/22
- Zillow Group acquires real estate media marketing company VRX Media
- 02/01/23
- ContextLogic introduces flat shipping rate to U.K. consumers
- 01/31/23
- ContextLogic to reduce workforce by roughly 17%
- 01/17/23
- Wish announces integrations with ShipStation and ShippingEasy
- 11/09/22
- ContextLogic sees Q4 adjusted EBITDA at ($110M) to ($90M)
- 02/02/23
- Texas Instruments CFO lays out expected benefits from CHIPS Act
- 01/24/23
- Texas Instruments says Q4 results reflect weaker demand in all end markets
- 01/19/23
- Texas Instruments names Haviv Ilan as next CEO, effective April 1
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 02/13/23
- Twilio winding down some perks, 'we've gotten too big,' says CEO
- 02/13/23
- Twilio names Aidan Viggiano as CFO, effective March 1
- 02/13/23
- Twilio to permanently close additional office locations
- 02/13/23
- Twilio sees Q4 results 'at or above' previously provided guidance ranges
- 02/13/23
- TreeHouse falls -6.1%
- 11/14/22
- Jana made new buy Freshpet top holding in Q3, also bought Momentive
- 11/07/22
- TreeHouse says FY23 revenue growth expected to be strong, cites pricing actions
- 08/15/22
- JANA Partners exits Zendesk, boosts stake in New Relic
- 02/09/23
- Teva settles price-fixing claims in Florida for $6.73M
- 02/08/23
- Teva sees FY23 free cash flow $1.7B-$2.1B
- 01/30/23
- Evoke Pharma says joint stipulation of dismissal filed in GIMOTI case
- 02/13/23
- Teradata rises 13.4%
- 02/13/23
- Teradata rises 10.0%
- 09/13/22
- Teradata, ActionIQ enter strategic relationship for HybridCompute Integration
- 01/09/23
- Sotera Health settles ethylene oxide litigation in Illinois for $408M
- 11/21/22
- Sotera Health business Sterigenics issues statement on Fornek trial
- 11/21/22
- Sotera Health trading resumes
- 11/21/22
- Sotera Health jumps after Sterigenics found not liable for woman's cancer
- 02/10/23
- Berkshire Grey confirms receipt of indication of interest from SoftBank Group
- 02/13/23
- Rocket Companies announces retirement of CEO Jay Farner and succession plan
- 12/14/22
- CEO of Rocket Companies Farner buys over $600K in company stock
- 11/02/22
- Rocket Companies CEO buys $598K in common stock
- 10/03/22
- Rocket Companies CFO Julie Booth to retire, Brian Brown to succeed
- 01/23/23
- Ritchie Bros., IAA merger expected to close in 1H23
- 02/02/23
- Qualcomm expects weak handset market to persist through 1H23
- 02/02/23
- Qualcomm sees Q2 QCT revenue $7.4B-$8B
- 02/02/23
- Qualcomm CEO says long-term trends driving demand 'intact'
- 01/31/23
- Mobile phone, PC shipments to fall another 4.4% in 2023, Gartner says
- 02/02/23
- Okta jumps 6% to $80.69 after announcing restructuring plan
- 02/02/23
- Okta announces restructuring plan, to cut 300 employees
- 01/12/23
- Okta says there will be some disruption from sales leadership changes
- 01/12/23
- authID integrates Verified CloudConnect with Okta Workforce Identity Cloud
- 02/12/23
- Ocular Therapeutix announces interim 10-month data from Phase 1 OTX-TKI trial
- 01/06/23
- Ocular Therapeutix provides 2022 update, reviews 2023 milestones
- 01/06/23
- Ocular Therapeutix sees cash runway through middle of 2024
- 12/12/22
- Titan Pharmaceuticals enters licensing agreement with Ocular Therapeutix
- 02/13/23
- U.S. video game spending fell 5% y/y in January, says NPD
- 02/09/23
- American Express expands relationship with Microsoft to develop travel solutions
- 02/08/23
- Fortinet launches Cybercrime Atlas initiative
- 02/08/23
- CMA says Microsoft-Activision deal 'could harm UK gamers'
- $145.43 /
+13.78 (+10.47%) - 02/13/23
- Appfire announces partnership with Monday.com
- 11/23/22
- Monday.com promotes Yoni Osherov to Chief Revenue Officer
- 10/25/22
- Monday.com opens latest North American office in Chicago
- 10/11/22
- Monday.com expands global presence with office in Marunouchi, Tokyo
- 02/13/23
- Meta Platforms Chief Business Officer Marne Levine leaving comapny
- 02/12/23
- Fly Intel: Top five weekend stock stories
- 02/09/23
- Meta Platforms exec sells $4.45M in common stock
- 02/09/23
- Meta Platforms completes acquisition of Within
- 02/10/23
- Manchester United suitors unsure Glazer family wants full club sale, ESPN says
- 02/08/23
- Manchester United rises 13.6%
- 02/08/23
- Manchester United rises 13.4%
- 02/08/23
- Manchester United rises 13.4%
- 01/29/23
- Fly Intel: Top five weekend stock stories
- 01/26/23
- Intel down 5% after Q4 report, Q1 guidance
- 01/26/23
- Intel CFO says 'took steps to right-size the organization' in Q4
- 01/23/23
- Intel names Frank Yeary new independent chair
- 02/01/23
- IBM, NASA collaborate to research impact of climate change with AI
- 01/25/23
- IBM says free cash flow was up $2.8B in 2022
- 01/25/23
- IBM sees FY23 revenue growth consistent with MSD model
- 01/10/23
- Intel unveils 4th Gen Xeon Scalable processors, Xeon CPU Max Series
- 02/13/23
- Luxor Capital files proxy materials to oppose Ritchie Bros., IAA merger
- 01/30/23
- Janus Henderson intends to vote against Ritchie Bros., IAA deal
- 01/24/23
- Luxor Capital comments on Ritchie Bros. restructuring of IAA deal
- 01/23/23
- IAA rises 6.6%
- 02/13/23
- G1 Therapeutics falls 33% to $4.75 after discontinuing phase 3 PRESERVE 1 trial
- 02/13/23
- G1 Therapeutics to discontinue phase 3 PRESERVE 1 trial
- 01/04/23
- G1 Therapeutics provides update on PRESERVE 3 trial
- 12/07/22
- G1 Therapeutics reports Phase 2 results of trilaciclib in breast cancer
- 02/09/23
- GM, GlobalFoundries enter long-term direct supply deal for semiconductor chips
- 02/09/23
- GlobalFoundries acquires Renesas' non-volatile resistive RAM technology
- 11/11/22
- GlobalFoundries seeks annualized savings of $200M, cutting jobs
- 10/17/22
- GlobalFoundries announces $30M in federal funding for GaN chips at Vermont fab
- $12.61 /
+2.735 (+27.71%) - 02/13/23
- Fastly rises 27.1%
- 02/13/23
- Fastly rises 19.1%
- 02/13/23
- Fastly rises 11.2%
- 11/15/22
- Fastly director sells $3.93M in common stock
- 01/09/23
- Five Below up 3% at $181.51 after guiding FY22 near high end of prior range
- 01/09/23
- Five Below CEO Joel Anderson says entering 2023 with momentum
- 12/06/22
- Five Below director sells $9.1M, CEO sells $1.9M in common stock
- 11/30/22
- Five Below sees FY22 comparable sales down 2%-3%
- $66.02 /
-9.455 (-12.53%) - 02/13/23
- FIS falls -13.8%
- 02/13/23
- FIS falls -15.5%
- 02/13/23
- FIS falls -13.1%
- 02/13/23
- FIS provides update on Enterprise Transformation Program
- 02/13/23
- Check Point: Cyberattacks growing, becoming more sophisticated
- 02/13/23
- Check Point sees FY23 operating margin around 22%
- 02/13/23
- Check Point Software introduces Quantum SD-WAN
- 02/13/23
- Check Point announces $2B expansion of share repurchase program
- 02/07/23
- Caterpillar director Dickinson sells 6,070 common shares
- 01/31/23
- Caterpillar expects healthy mining demand
- 01/31/23
- Caterpillar: Pockets of supply chain challenges remain
- 01/06/23
- Caterpillar to invest in Lithos Energy
- 02/13/23
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- 12/07/22
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY
- 11/28/22
- Axsome Therapeutics says AXS-05 achieves primary endpoint in ACCORD trial
- 11/07/22
- Axsome Therapeutics expects cash to fund operations into 2025
- $601.20 /
+6.825 (+1.15%) - 01/25/23
- U.K. antitrust agency opens investigation into Broadcom, VMware deal
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- 12/15/22
- Broadcom announces availability of CA 1 Flexible Storage soution
- 12/08/22
- Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M
- 02/13/23 Evercore ISI
- Zillow Group upgraded to Outperform at Evercore on five 'key factors'
- 02/13/23 Evercore ISI
- Zillow Group upgraded to Outperform from In Line at Evercore ISI
- 02/07/23 Piper Sandler
- Zillow Group price target raised to $40 from $31 at Piper Sandler
- 01/09/23 BofA
- Zillow Group upgraded to Buy from Underperform at BofA
- 02/13/23 BofA
- BofA sees room for additional efficiencies at Meta
- 02/10/23 Tigress Financial
- Meta Platforms price target raised to $285 from $260 at Tigress Financial
- 02/08/23 Loop Capital
- Meta Platforms price target raised to $188 from $165 at Loop Capital
- 02/03/23 DA Davidson
- Amazon.com price target raised to $134 from $114 at DA Davidson
- $66.02 /
-9.455 (-12.53%) - 02/14/23 Credit Suisse
- FIS downgraded to Neutral at Credit Suisse on disappointing FY23 outlook
- 02/14/23 Credit Suisse
- FIS downgraded to Neutral from Outperform at Credit Suisse
- 02/14/23 Baird
- FIS price target lowered to $80 from $84 at Baird
- 02/14/23 Barclays
- FIS price target lowered to $68 from $73 at Barclays
- 02/13/23 Jefferies
- Twilio restructuring shifts focus into earnings, says Jefferies
- 02/13/23 Stifel
- Twilio price target raised to $60 from $45 at Stifel
- 02/13/23 Baird
- Baird positive on Twilio's restructuring plans, cost reductions
- 01/17/23 Piper Sandler
- Twilio price target lowered to $69 from $79 at Piper Sandler
- $145.43 /
+13.78 (+10.47%) - 02/14/23 Canaccord
- Monday.com price target raised to $160 from $120 at Canaccord
- 02/14/23 TD Cowen
- Monday.com price target raised to $175 from $165
- 02/14/23 Credit Suisse
- Monday.com price target raised to $170 from $140 at Credit Suisse
- 02/14/23 KeyBanc
- Monday.com price target raised to $180 from $156 at KeyBanc
- 02/14/23 TD Cowen
- Teradata price target raised to $40 from $36 at Cowen
- 02/14/23 Barclays
- Teradata price target raised to $35 from $33 at Barclays
- 01/26/23 Guggenheim
- Teradata initiated with a Neutral at Guggenheim
- 12/12/22 RBC Capital
- Coupa Software upgraded to Sector Perform from Underperform at RBC Capital
- 01/10/23 JPMorgan
- Rocket Companies price target raised to $8 from $7 at JPMorgan
- 01/09/23 Credit Suisse
- Rocket Companies downgraded to Underperform from Neutral at Credit Suisse
- 01/06/23 Barclays
- Rocket Companies price target raised to $6 from $4.50 at Barclays
- 11/16/22 Argus
- Rocket Companies cut to Sell at Argus on decline in mortgage originations
- 02/13/23 Baird
- Caterpillar downgraded to Neutral from Outperform at Baird
- 02/07/23 BMO Capital
- Caterpillar price target raised to $230 from $210 at BMO Capital
- 02/01/23 Wells Fargo
- Caterpillar price target raised to $240 from $228 at Wells Fargo
- 02/01/23 Credit Suisse
- Caterpillar price target raised to $306 from $290 at Credit Suisse
- $12.61 /
+2.735 (+27.71%) - 02/13/23 BofA
- Fastly double upgraded to Buy at BofA on intermediate-term potential
- 02/13/23 BofA
- Fastly upgraded to Buy from Underperform at BofA
- 11/21/22 Credit Suisse
- Fastly initiated with a Neutral at Credit Suisse
- 02/13/23 Roth MKM
- Five Below upgraded to Buy from Neutral at Roth MKM
- 02/10/23
- Gordon Haskett upgrades Five Below to Buy on growth confidence
- 02/10/23
- Five Below upgraded to Buy from Accumulate at Gordon Haskett
- 02/07/23 Barclays
- Barclays sees a 'reset' in U.S. retail but 'not a recession yet'
- 02/14/23 Goldman Sachs
- Okta initiated with a Sell at Goldman Sachs
- 02/13/23 BofA
- BofA starts Okta at Underperform with 'no positive catalysts in sight'
- 02/13/23 BofA
- Okta initiated with an Underperform at BofA
- 02/03/23 RBC Capital
- Okta price target raised to $95 from $80 at RBC Capital
- 12/09/22 Deutsche Bank
- Manchester United downgraded to Hold from Buy at Deutsche Bank
- 11/23/22 Jefferies
- Jefferies expects 'competitive process' for Manchester United
- 06/02/22 Deutsche Bank
- Manchester United undervalued after selloff, says Deutsche Bank
- 03/21/22 Deutsche Bank
- Manchester United upgraded on 'value disconnect' at Deutsche Bank
- 12/06/22 JPMorgan
- SoftBank Group downgraded to Neutral from Overweight at JPMorgan
- 11/29/22 Citi
- SoftBank Group downgraded to Neutral from Buy at Citi
- 11/14/22 Jefferies
- SoftBank Group downgraded to Underperform from Hold at Jefferies
- 10/26/22 Jefferies
- SoftBank Group downgraded to Hold from Buy at Jefferies
- 12/13/22 Citi
- ContextLogic initiated with a Sell at Citi
- 08/10/22 Credit Suisse
- ContextLogic free cash flow to improve from here, says Credit Suisse
- 03/22/22 Loop Capital
- ContextLogic cut to Hold at Loop Capital on inflation and and European exposure
- 03/22/22 Loop Capital
- ContextLogic downgraded to Hold from Buy at Loop Capital
- 02/13/23 Morgan Stanley
- Morgan Stanley sees 5 quarters of accelerating EPS growth at Microsoft after Q2
- 02/10/23 Roth MKM
- Activision Blizzard price target lowered to $88 from $95 at Roth MKM
- 02/10/23 Jefferies
- Jefferies positive on Alphabet AI advantages, says 'stock hit overdone'
- 02/13/23 H.C. Wainwright
- Ocular Therapeutix price target raised to $11 from $9 at H.C. Wainwright
- 01/09/23 JMP Securities
- Ocular Therapeutix price target lowered to $12 from $25 at JMP Securities
- 11/08/22 H.C. Wainwright
- Ocular Therapeutix price target lowered to $9 from $10 at H.C. Wainwright
- 11/08/22 Raymond James
- Ocular Therapeutix price target lowered to $14 from $29 at Raymond James
- 01/30/23 JPMorgan
- G1 Therapeutics upgraded to Neutral into data catalysts at JPMorgan
- 01/30/23 JPMorgan
- G1 Therapeutics upgraded to Neutral from Underweight at JPMorgan
- 01/04/23 EF Hutton
- G1 Therapeutics initiated with a Buy at EF Hutton
- 01/03/23 Needham
- G1 Therapeutics named as Top Pick, added to Conviction list at Needham
- 01/30/23 Mizuho
- Axsome Therapeutics price target raised to $86 from $80 at Mizuho
- 01/05/23 Piper Sandler
- Axsome Therapeutics initiated with a Neutral at Piper Sandler
- 01/03/23 BTIG
- Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
- 12/23/22 BTIG
- Axsome Therapeutics price target raised to $98 from $62 at BTIG
- 02/13/23 Barclays
- ZIM Integrated downgraded to Underweight from Equal Weight at Barclays
- 11/18/22 Barclays
- ZIM Integrated price target lowered to $26.50 from $63 at Barclays
- 09/20/22 Goldman Sachs
- ZIM Integrated price target lowered to $30 from $60 at Goldman Sachs
- 08/23/22 Citi
- ZIM Integrated downgraded to Neutral from Buy at Citi
- 02/09/23 Barclays
- Teva price target raised to $14 from $13 at Barclays
- 01/23/23 Piper Sandler
- ANDA filing for generic Firdapse not a surprise, says Piper Sandler
- 01/19/23 Jefferies
- Teva downgraded to Hold from Buy at Jefferies
- 01/06/23 Northland
- Alvotech named a top pick for 2023 at Northland
- 08/09/22 Truist
- TreeHouse price target raised to $60 from $50 at Truist
- 08/08/22 Stifel
- TreeHouse price target raised to $45 from $38 at Stifel
- 06/27/22 Stifel
- TreeHouse meal prep sale could bring higher multiple, says Stifel
- 05/23/22 Truist
- TreeHouse upgraded to Buy from Hold at Truist
- 02/14/23 Citi
- Check Point price target lowered to $129 from $130 at Citi
- 02/14/23 Goldman Sachs
- Check Point initiated with a Buy at Goldman Sachs
- 02/13/23 FBN Securities
- Check Point price target lowered to $150 from $155 at FBN Securities
- 02/09/23 Loop Capital
- Fortinet price target raised to $80 from $66 at Loop Capital
- 01/23/23 JPMorgan
- Sotera Health upgraded to Neutral from Underweight at JPMorgan
- 01/10/23 Wolfe Research
- Sotera Health upgraded to Outperform at Wolfe Research after Illinois settlement
- 01/10/23 Wolfe Research
- Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research
- 01/10/23 Barclays
- Sotera Health double-upgraded to Overweight from Underweight at Barclays
- 01/24/23 Raymond James
- Ritchie Bros. price target raised to $60 from $55 at Raymond James
- 01/24/23 Baird
- Ritchie Bros. price target raised to $66 from $62 at Baird
- 01/05/23 Baird
- IAA downgraded to Neutral from Outperform at Baird
- 12/05/22 Scotiabank
- Ritchie Bros. upgraded to Outperform at Scotiabank after deal-driven pullback
- 02/13/23 Credit Suisse
- Buyback rule tied to CHIPS Act would be 'significant' for TI, says Credit Suisse
- 02/13/23 Citi
- January notebook shipments above expectations, says Citi
- 02/01/23 Morgan Stanley
- AMD's softer outlook 'still could be a relief' after Intel, says Morgan Stanley
- 02/01/23 Credit Suisse
- AMD price target raised to $96 from $90 at Credit Suisse
- 02/06/23 Edward Jones
- IBM downgraded to Hold from Buy at Edward Jones
- 01/31/23 Evercore ISI
- IBM removed from 'Tactical Outperform' list at Evercore ISI
- 01/26/23 BMO Capital
- IBM price target raised to $155 from $148 at BMO Capital
- 01/26/23 Morgan Stanley
- IBM price target lowered to $143 from $148 at Morgan Stanley
- 02/05/23 Citi
- Qualcomm price target raised to $132 from $105 at Citi
- 02/03/23 BofA
- Qualcomm expectations have likely reached trough, says BofA
- 02/03/23 TD Cowen
- Qualcomm price target lowered to $155 from $165 at Cowen
- 02/03/23 Wells Fargo
- Qualcomm price target raised to $130 from $105 at Wells Fargo
- 02/03/23 Susquehanna
- Texas Instruments price target raised to $210 from $205 at Susquehanna
- 02/02/23 Evercore ISI
- Evercore ISI sees few surprises as TI outlines plans to support growth
- 01/25/23 BMO Capital
- Texas Instruments price target raised to $215 from $195 at BMO Capital
- $601.20 /
+6.825 (+1.15%) - 02/07/23 UBS
- VMware price target raised to $147 from $131 at UBS
- 01/23/23 Truist
- Broadcom price target lowered to $659 from $662 at Truist
- 01/11/23 KeyBanc
- KeyBanc says iPhone survey shows supply partial recovery, some shortages remain
- 01/10/23 Piper Sandler
- Piper Sandler sees no strategic reason for Apple to insource Wi-Fi combo chip
- 01/23/23 Loop Capital
- GlobalFoundries initiated with a Buy at Loop Capital
- 12/14/22 Deutsche Bank
- GlobalFoundries price target raised to $70 from $67 at Deutsche Bank
- 11/15/22 Credit Suisse
- GlobalFoundries assumed with an Outperform at Credit Suisse
- 11/16/22
- ZIM Integrated lowers FY22 adjusted EBITDA view to $7.4B-$7.7B from $7.8B-$8.2B
- 11/16/22
- ZIM Integrated reports Q3 EPS $9.66, consensus $9.54
- 08/17/22
- ZIM Integrated backs FY22 adjusted EBITDA view $7.8B-$8.2B
- 08/17/22
- ZIM Integrated reports Q2 EPS $11.07, consensus $12.84
- 11/02/22
- Zillow Group sees Q4 revenue $395M-$425M, consensus $433.1M
- 11/02/22
- Zillow Group reports Q3 adjusted EBITDA $130M
- 11/02/22
- Notable companies reporting after market close
- 11/09/22
- ContextLogic reports Q3 EPS (18c), consensus (20c)
- 01/24/23
- Texas Instruments sees Q1 EPS $1.64-$1.90, consensus $1.87
- 01/24/23
- Texas Instruments reports Q4 EPS $2.13, consensus $1.98
- 10/25/22
- Texas Instruments sees Q4 EPS $1.83-$2.11, consensus $2.21
- 11/03/22
- Twilio sees Q4 EPS (11c)-(6c), consensus (12c)
- 11/03/22
- Twilio pulls 30%-plus revenue growth target, says not achievable
- 11/03/22
- Twilio reports Q3 EPS (27c), consensus (36c)
- 11/03/22
- Notable companies reporting after market close
- 02/13/23
- TreeHouse reports Q4 adjusted EPS 98c, consensus 92c
- 11/07/22
- TreeHouse sees Q4 continuing operations revenue up 22%-24%, consensus $1.43B
- 11/07/22
- TreeHouse reports Q3 adjusted EPS 30c, consensus 16c
- 02/08/23
- Teva sees FY23 EPS $2.25-$2.55, consensus $2.52
- 02/08/23
- Teva reports Q4 EPS 71c, consensus 71c
- 11/03/22
- Teva backs FY22 EPS view $2.40-$2.60, consensus $2.50
- 11/03/22
- Teva reports Q3 EPS 59c, consensus 62c
- 02/13/23
- Teradata sees Q1 EPS 60c- 64c , consensus 59c
- 02/13/23
- Teradata sees FY23 EPS $1.90-$2.06, consensus $1.89
- 02/13/23
- Teradata reports Q4 EPS 35c, consensus 30c
- 11/07/22
- Teradata narrows FY22 EPS view to $1.58-$1.62, consensus $1.60
- 02/13/23
- Sotera Health reaffirms 2022 revenue view $995M-$1.005B, consensus $1B
- 11/02/22
- Sotera Health lowers FY22 adjusted EPS view to 91c-95c from 93c-97c
- 11/02/22
- Sotera Health reports Q3 adjusted EPS 23c, consensus 22c
- 02/13/23
- Rocket reaffirms Q4 adjusted revenue view $600M-$750M, consensus $682.73M
- 11/04/22
- Rocket Companies sees Q4 adjusted revenue $600M-$750M, consensus $1.05B
- 11/03/22
- Rocket Companies reports Q3 adjusted EPS (8c), consensus (3c)
- 02/13/23
- Ritchie Bros. sees Q4 revenue $444M, consensus $410.57M
- 11/07/22
- Ritchie Bros. reports Q3 adjusted EPS 53c, consensus 49c
- 02/02/23
- Qualcomm sees Q2 adjusted EPS $2.05-$2.25, consensus $2.26
- 02/02/23
- Qualcomm reports Q1 adjusted EPS $2.37, consensus $2.34
- 02/02/23
- Notable companies reporting after market close
- 11/02/22
- Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42
- 11/30/22
- Okta raises FY23 EPS view to (27c)-(26c) from (73c)-(70c), consensus (72c)
- 11/30/22
- Okta sees Q4 adjusted EPS 9c-10c, consensus (11c)
- 11/30/22
- Okta reports Q3 adjusted EPS 0c, consensus (24c)
- 11/30/22
- Notable companies reporting after market close
- 01/06/23
- Ocular Therapeutix sees Q4 product revenue $13.6M
- 11/07/22
- Ocular Therapeutix sees 2022 net product revenue $48M-$52M
- 11/07/22
- Ocular Therapeutix reports Q3 EPS (31c), consensus (24c)
- 01/24/23
- Microsoft reports Q2 adjusted EPS $2.32, consensus $2.29
- 01/24/23
- Notable companies reporting after market close
- 10/25/22
- Microsoft sees FX decreasing total revenue growth by 5% in FY23
- 10/25/22
- Microsoft reports Q1 EPS $2.35, consensus $2.30
- $145.43 /
+13.78 (+10.47%) - 02/13/23
- Monday.com seesFY23 revenue $$688M-$693M , consensus $661.74M
- 02/13/23
- Monday.com sees Q1 revenue $154M-$156M, consensus $150.12M
- 02/13/23
- Monday.com reports Q4 EPS 44c, consensus 37c
- 11/14/22
- Monday.com reports Q3 EP 5c consensus (54c)
- 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 12/08/22
- Manchester United reports Q2 adjusted EBITDA GBP 23.6M vs. GBP 11.2M y/y
- 09/22/22
- Manchester United sees FY23 revenue GBP 580M-GBP 600M
- 09/22/22
- Manchester United reports Q4 adjusted EPS (GBP 12.38) vs. (GBP 20.67) last year
- 01/26/23
- Intel sees Q1 EPS (15c), consensus 24c
- 01/26/23
- Intel reports Q4 EPS 10c, consensus 20c
- 01/26/23
- Notable companies reporting after market close
- 12/05/22
- Intel sees down Q1 sales down 5%-7% as 'right starting point for seasonality'
- 01/25/23
- IBM sees FY23 revenue growth consistent with mid-single digit model
- 01/25/23
- IBM reports Q4 adjusted EPS $3.60, consensus $3.60
- 01/25/23
- Notable companies reporting after market close
- 10/19/22
- IBM reports Q3 Software revenue $5.8B, up 14.2% in constant currency
- 02/13/23
- IAA reports preliminary Q4 revenue $524M, consensus $535.21M
- 11/07/22
- IAA reports Q3 adjusted EPS 45c, consensus 50c
- 11/02/22
- G1 Therapeutics reports Q3 EPS (59c), consensus (63c)
- 02/13/23
- Notable companies reporting before tomorrow's open
- 11/08/22
- GlobalFoundries sees Q4 adjusted EPS $1.24-$1.44, consensus $1.01
- 11/08/22
- GlobalFoundries reports Q3 adjusted EPS 67c, consensus 62c
- $12.61 /
+2.735 (+27.71%) - 11/02/22
- Fastly reaffirms FY22 EPS view (67c)-(63c), consensus (65c)
- 11/02/22
- Fastly sees Q4 EPS (15c)-(11c), consensus (10c)
- 11/02/22
- Fastly reports Q3 EPS (14c), consensus (17c)
- 01/09/23
- Five Below sees Q4 and FY22 'near high end of prior guidance ranges'
- 11/30/22
- Five Below raises FY22 EPS view to $4.55$4.71 from $4.26-$4.56, consensus $4.41
- 11/30/22
- Five Below sees Q4 EPS $2.93-$3.09, consensus $2.93
- 11/30/22
- Five Below reports Q3 EPS 29c, consensus 14c
- $66.02 /
-9.455 (-12.53%) - 02/13/23
- FIS sees FY23 adjusted EPS $5.70-$6.00, consensus $6.57
- 02/13/23
- FIS sees Q1 adjusted EPS $1.17-$1.23, consensus $1.42
- 02/13/23
- FIS reports Q4 adjusted EPS $1.71, consensus $1.70
- 11/03/22
- FIS sees FY22 EPS $6.60-$6.66, consensus $7.02
- 02/13/23
- Check Point sees Q1 adjusted EPS $1.68-$1.78, consensus $1.75
- 02/13/23
- Check Point sees FY23 adjusted EPS $7.70-$8.30, consensus $8.09
- 02/13/23
- Check Point reports Q4 EPS $2.45, consensus $2.19
- 10/27/22
- Check Point narrows FY22 EPS view to $7.20-$7.40, consensus $7.22
- 01/31/23
- Caterpillar reports Q4 adjusted EPS $3.86, consensus $4.02
- 01/30/23
- Notable companies reporting before tomorrow's open
- 10/27/22
- Caterpillar reports Q3 adjusted EPS $3.95, consensus $3.16
- 11/07/22
- Axsome Therapeutics reports Q3 EPS ($1.07), consensus ($1.08)
- $601.20 /
+6.825 (+1.15%) - 12/08/22
- Broadcom sees Q1 revenue $8.9B, consensus $8.79B
- 12/08/22
- Broadcom reports Q4 EPS $10.45, consensus $10.28
- 12/08/22
- Notable companies reporting after market close
- 09/01/22
- Broadcom sees Q4 revenue $8.9B, consensus $8.73B
|
Hot Stocks
|
In a regulatory filing… In a regulatory filing earlier, Axsome Therapeutics (AXSM) disclosed that on February 10, the company received a Paragraph IV Certification Notice Letter from Teva Pharmaceuticals (TEVA), providing notification to the company that Teva has submitted an Abbreviated New Drug Application, or "ANDA," to the U.S. Food and Drug Administration seeking approval to manufacture, use, or sell a generic version of Auvelity, or dextromethorphan HBr-bupropion HCl. "In the Notice Letter, Teva alleges that four of the patents listed in the FDA Orange Book for Auvelity, U.S. Patent Numbers 10,780,064; 10,925,842; 10,940,124; and 10,966,942, each of which expires in 2040, are invalid, unenforceable, or will not be infringed by Teva's manufacture, use, or sale of the generic product described in its ANDA submission. The Paragraph IV Certification does not challenge any of the remaining Orange Book listed patents for Auvelity which have expirations out to 2034," Axsome stated in the filing. ShowHide Related Items >><< - 02/09/23
- Teva settles price-fixing claims in Florida for $6.73M
- 02/08/23
- Teva sees FY23 free cash flow $1.7B-$2.1B
- 01/30/23
- Evoke Pharma says joint stipulation of dismissal filed in GIMOTI case
- 01/23/23
- Catalyst comments on the FDA's position on orphan drug exclusivity
- 12/07/22
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY
- 11/28/22
- Axsome Therapeutics says AXS-05 achieves primary endpoint in ACCORD trial
- 11/07/22
- Axsome Therapeutics expects cash to fund operations into 2025
- 01/30/23 Mizuho
- Axsome Therapeutics price target raised to $86 from $80 at Mizuho
- 01/05/23 Piper Sandler
- Axsome Therapeutics initiated with a Neutral at Piper Sandler
- 01/03/23 BTIG
- Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
- 12/23/22 BTIG
- Axsome Therapeutics price target raised to $98 from $62 at BTIG
- 02/09/23 Barclays
- Teva price target raised to $14 from $13 at Barclays
- 01/23/23 Piper Sandler
- ANDA filing for generic Firdapse not a surprise, says Piper Sandler
- 01/19/23 Jefferies
- Teva downgraded to Hold from Buy at Jefferies
- 01/06/23 Northland
- Alvotech named a top pick for 2023 at Northland
- 02/08/23
- Teva sees FY23 EPS $2.25-$2.55, consensus $2.52
- 02/08/23
- Teva reports Q4 EPS 71c, consensus 71c
- 11/03/22
- Teva backs FY22 EPS view $2.40-$2.60, consensus $2.50
- 11/03/22
- Teva reports Q3 EPS 59c, consensus 62c
- 11/07/22
- Axsome Therapeutics reports Q3 EPS ($1.07), consensus ($1.08)
- 11/03/22
- Teva won't renew contract of CEO Kare Schultz, WSJ reports
- 10/07/22
- Teva tells Bloomberg it sees Adderall supply issues for next 2-3 months
- 08/17/22
- Generic drugmakers paid to settle first Zantac case before trial, Bloomberg says
- 01/23/23
- What You Missed On Wall Street This Morning
- 01/19/23
- What You Missed On Wall Street On Thursday
- 01/19/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/22/22
- What You Missed On Wall Street On Thursday
- 01/25/23
- Fly Intel: After-Hours Movers
- 11/30/22
- Biotech Alert: Searches spiking for these stocks today
- 11/28/22
- What You Missed On Wall Street On Monday
- 11/28/22
- What You Missed On Wall Street This Morning
- 01/10/23
- Unusually active option classes on open January 10th
- 01/04/23
- Unusually active option classes on open January 4th
- 01/03/23
- Teva call volume above normal and directionally bullish
- 12/22/22
- Teva call volume above normal and directionally bullish
- 12/12/22
- AXSOME call volume above normal and directionally bullish
- 10/17/22
- Axsome Therapeutics call volume above normal and directionally bullish
- 10/07/22
- Axsome Therapeutics call volume above normal and directionally bullish
- 09/09/22
- Axsome Therapeutics call volume above normal and directionally bullish
|